Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 2, 1997, Pages 114-117

  Amiral, J ^a   Lormeau, J C ^b   Marfaing Koka, A ^c   Vissac, A M ^a   Wolf, M ^c   Boyer Neumann, C ^c   Tardy, B ^d   Herbert, J M ^b   Meyer, D ^c  

^a Serbio   (France)

^b SANOFI   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

heparin induced thrombocytopenia; immunogenicity; pentasaccharide; platelet factor 4

Indexed keywords

FONDAPARINUX; HEPARIN; PENTASACCHARIDE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CROSS REACTION; FEMALE; HUMAN; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030980765     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199703000-00005     Document Type: Article

References (18)

1. Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
2. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73: 21-28.
3. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-251.
4. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-439.
5. Visentin GP, Aster RH. Heparin-induced thrombo-cytopenia and thrombosis. Curr Opin Hematol 1995; 2: 351-357.
6. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
7. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554-561.
8. Chong BH. Failure of orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome. Br J Haematol 1995; 90: 969-973.
9. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-1596.
10. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381-385.
11. Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie JP, Samama M M. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 1384-1385.
12. Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatti G. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for anti-thrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Comm 1983; 116: 492-499.
13. Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198.
14. Hobbelen PMJ, Van Dinther TG, Vogel GM, Van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthetized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 266-270.
15. Messmore HL, Griffin B, Fareed J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989; 556: 217-231.
16. Boneu B, Necciari J, Cariou R, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107A/ORG31540) with high affinity to antithrombin III. Thromb Haemost 1995; 74: 1468-1473.
17. Huisse MG, Guillin MC, Bezeaud A, Toulemonde F, Kitzis M, Andreassian B. Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions. Thromb Res 1982; 27: 485-490.
18. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 886-892.